NCT07891286
Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 1 with changes below, 1 re-verified with no change.
- Study First Submitted
Endpoints
Primary
Determine whether treatment with mirdametinib results in objective decreases in the largest diameter of LGCMN
Timeframe: Pre-treatment and for up to 24 months on treatment.
Secondary (6)
Feasibility of evaluating LGCMN thickness by MRI
Determine whether mirdametinib treatment reduces the number of satellite nevi (nevi in addition to the largest target nevus) when they are present
Evaluate the safety of mirdametinib in participants with LGCMN
Determine whether mirdametinib treatment results in improvement of itching QOL measures in participants with LGCMN
Evaluate the feasibility of evaluating pERK as a pharmacodynamic marker for mirdametinib response in serial biopsies of LGCMN
Show 1 moreShow less
Determine whether cutaneous or extracutaneous melanoma occurs in participants with LGCMN while on or after mirdametinib treatment
Arms and interventions
Arm 1Experimental
Mirdametinib will be administered orally, twice daily on an intermittent dosing schedule (3 weeks on, 1 week off). The dosage will be 2-4 mg/m2/dose.
Drugs: Mirdametinib
Sites
1 site in 1 country
- National Institutes of Health Clinical CenterBethesda, Maryland, United States